The document is a regulatory filing containing the transcript of the Q1 FY27 Earnings Conference Call held on August 5, 2026, submitted pursuant to SEBI Listing Regulations.
The conference call was held to discuss the company's financial and operational performance for the first quarter of fiscal year 2027 (Q1 FY27).
Management participants included:
Mr. Sameer Kothari – Managing Director
Mr. Mayank Samdani – Group Chief Financial Officer
Mr. Ganesh Argekar – Executive Director
Mr. Vimal Solanki - Head of Corporate Communications
SGA – Investor Relations Advisor
The company stated that no unpublished price sensitive information (UPSI) would be shared during the call.
The earnings presentation was uploaded on stock exchanges and the company website prior to the call.
Financial Highlights Discussed
Q1 FY27 Financial Performance:
Total Income: INR1,207 crores (18% YoY growth)
EBITDA: INR106.3 crores (26% YoY growth)
Profit Before Tax: INR56.6 crores (33% YoY growth)
Profit After Tax: INR42.8 crores (33% YoY growth) - Highest ever quarterly PAT
Footwear Division Impact: Temporary cost pressures resulted in ~INR6 crores impact due to:
Higher raw material prices from Middle East crisis
Implementation of revised wage rates in Haryana (30%+ increase)
Employee cost of shoe division represents 35-40% of total employee cost
Capital Expenditure:
New projects signed: INR340 crores for FY27
Projects carried forward from FY26: INR150 crores
Total planned FY27 capex: ~INR500 crores (expected to exceed FY26 record)
FY27 Guidance: PAT guidance reaffirmed at INR200-220 crores, representing 34-48% growth over FY26.
Operational Highlights
Home and Personal Care: At maximum capacity with record performance; Aurangabad integration completed; Silvassa brownfield expansion to commence Q2; Lucknow greenfield on track.
Food and Beverages: Healthy momentum across categories; Coimbatore, Nashik, Mysore at record production; excellent beverage season; adding Greek yogurt facility in Goa.
Healthcare: Adding new customers across syrup, tablets, lozenges; progressing ayurvedic wellness expansion at Baddi; initiating Class III medical devices certification at Chennai for international markets.
Footwear: Steady progress with new customers; manufacturing capacities expanding across North and South India; order book full from Q2 FY27 onwards; expecting return to profitability in coming months.
Silvassa Disruption: Partial production restored after record rainfall in July; expected fully operational by end-August; adequately insured with no material long-term impact expected.
Additional Notes
The document includes the complete transcript of the earnings conference call with analyst Q&A session.
The company emphasized its diversified manufacturing platform and customer-led approach to investments.
GST duty inversion continues to affect cash flows in some business units.
The company is exploring export opportunities to US, UK, EU markets, though some are on hold due to tariff and freight situations.